Healthcare Services

One of the Major Drivers of the Corneal Endothelial Dystrophy Market Is the Growing Demand For Corneal Transplantation Driving The Market

March 31, 2026March 31, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Corneal Endothelial Dystrophy Market Projected To Become By 2030 Based On Its 2026 Valuation?

The corneal endothelial dystrophy market has experienced robust expansion in recent years. It is anticipated to increase from $184.84 billion in 2025 to $199.77 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 8.1%. Key factors contributing to its historical growth include the genetic prevalence of corneal disorders, limited early detection methods, the continued reliance on surgical intervention, the growth of the aging population, and specialized hospital-based treatment availability.

The corneal endothelial dystrophy market size is projected to undergo significant expansion in the coming years. It is forecast to reach $269.98 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.8%. The impetus for this growth during the forecast period stems from advancements in corneal imaging, greater accessibility to eye care, the emergence of specialty eye clinics, increased understanding of rare eye conditions, and innovations in corneal therapies. Noteworthy trends for the upcoming period include the increasing uptake of advanced corneal diagnostics, a rise in the utilization of minimally invasive treatments, an intensified focus on early genetic diagnosis, the expansion of specialized ophthalmic care, and improved monitoring of surgical outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21158&type=smp

What Primary Drivers Are Shaping The Development Of The Corneal Endothelial Dystrophy Market?

The expanding requirement for corneal transplantation is projected to propel the development of the corneal endothelial dystrophy market. Corneal transplantation is a surgical process where a damaged or diseased cornea is substituted with a healthy donor cornea to regain sight and improve eye health. The impetus behind this demand for corneal transplantations comes from the growing occurrence of corneal ailments, innovations in surgical techniques, and enhanced organ donation rates. In the context of corneal endothelial dystrophy, corneal transplantation serves as a treatment by replacing the compromised endothelium with healthy donor tissue, aiming to restore corneal clarity, mitigate edema, and improve vision. For example, in 2023, the Eye Bank Association of America, a US-based transplant association, noted an increase of 2.7% in domestic keratoplasty (a form of corneal transplantation) procedures, rising from 49,597 in 2022 to 50,925. This escalating need for corneal transplantation is thus a key driver for the growth of the corneal endothelial dystrophy market.

What Segment Groups Are Identified Within The Corneal Endothelial Dystrophy Market?

The corneal endothelial dystrophy market covered in this report is segmented –

1) By Treatment: Phototherapeutic Keratectomy, Amniotic Membrane Transplants, Anterior Stromal Puncture, Conjunctival Flaps

2) By Disease Type: Congenital Hereditary Endothelial Dystrophy 1, Congenital Hereditary Endothelial Dystrophy 2, Posterior Polymorphous Corneal Dystrophy, Fuchs Endothelial Corneal Dystrophy

3) By Diagnosis: Cornea Examination And Grading, Corneal Tomography, Corneal Pachymetry, Corneal Cell Count

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Phototherapeutic Keratectomy: Excimer Laser Therapy, Corneal Reshaping

2) By Amniotic Membrane Transplants: Fresh Amniotic Membrane Transplant, Cryopreserved Amniotic Membrane Transplant

3) By Anterior Stromal Puncture: Manual Technique, Laser-Assisted Technique

4) By Conjunctival Flaps: Partial Flap Technique, Full Flap Technique

Which Trends Are Influencing The Corneal Endothelial Dystrophy Market?

Major companies in the corneal endothelial dystrophy market are concentrating on advancing innovative treatments, such as allogeneic cell therapy, to tackle unmet medical needs by providing pioneering, minimally invasive options that enhance patient outcomes. Allogeneic cell therapy involves the utilization of cells from a donor of the same species, though genetically distinct, for treating a recipient. For instance, in September 2024, Aurion Biotech Inc., a US-based clinical-stage biotech firm, introduced Vyznova (neltependocel) in Japan to address bullous keratopathy, a corneal endothelial disease. Vyznova (neltependocel) is a cell therapy created by Aurion Biotech for bullous keratopathy, a condition that harms corneal endothelial cells and leads to visual impairments. It marks the first approved cell therapy for corneal endothelial disease and has received approval in Japan. Vyznova leverages corneal endothelial cells cultivated in a laboratory, making it possible to produce up to 1,000 doses from a single donor. This cutting-edge treatment presents a less invasive alternative to corneal transplants, assisting in alleviating the shortage of donor corneas and delivering a novel method to restore vision for patients with corneal diseases.

Which Companies Hold Significant Positions In The Corneal Endothelial Dystrophy Market?

Major companies operating in the corneal endothelial dystrophy market are Abbvie (Allergan plc), Alcon Inc., Bausch Health+Lomb, Santen Pharmaceutical Co Ltd, Lumenis Ltd, Carl Zeiss Meditec AG, Keeler Limited, ProQR Therapeutics NV, Rugby Laboratories, Blumont Healthcare Ltd, Grevis Pharmaceuticals Pvt Ltd, Rayner Group, Trefoil Therapeutics, Design Therapeutics, Horus Pharma, Stealth BioTherapeutics Corp, Surrozen Inc, Price Vision Group LLC, Invirsa Inc, KeraMed Inc, Massachusetts Eye and Ear, MediciBIO Co LTD, Prime Medicine Inc, AJL Ophthalmic SA

Read the full corneal endothelial dystrophy market report here:

https://www.thebusinessresearchcompany.com/report/corneal-endothelial-dystrophy-global-market-report

How Does The Corneal Endothelial Dystrophy Market Perform Across Major Global Regions?

North America was the largest region in the corneal endothelial dystrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the corneal endothelial dystrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Corneal Endothelial Dystrophy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=21158&type=smp

Browse Through More Reports Similar to the Global Corneal Endothelial Dystrophy Market 2026, By The Business Research Company

Antibody Discovery Global Market Report

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Monoclonal Antibodies Global Market Report

https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report

Non Starch Polysaccharide Nsp Enzyme Global Market Report

https://www.thebusinessresearchcompany.com/report/non-starch-polysaccharide-nsp-enzyme-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795